Literature DB >> 23683967

[Patients' characteristics and clinical management of atrial fibrillation in primary healthcare in Spain: FIATE Study].

José María Lobos-Bejarano1, José Carlos del Castillo-Rodríguez, Amparo Mena-González, José J Alemán-Sánchez, Antonio Cabrera de León, Gonzalo Barón-Esquivias, Agustín Pastor-Fuentes.   

Abstract

BACKGROUND AND OBJECTIVES: The main therapeutic objective in atrial fibrillation (AF) patients is stroke prevention. This study is aimed to determine whether the anticoagulant therapy may be appropriate regarding to the Guidelines and patients' profile in primary healthcare in Spain. PATIENTS AND METHODS: A national, multicenter, cross-sectional study of AF patients attended in primary healthcare in Spain has been conducted. The study involved 185 family physicians whose patients were randomized.
RESULTS: A total of 3,759 AF patients were randomized from the clinical records, and 2,070 were included in the study, at an average age of 74 (11) years old (50.7% female). Most of them (78%) had permanent AF and high comorbidity rates (hypertension 75%, obesity 30%, diabetes 27%, heart failure 20%, coronary heart disease 17%, and social risk 15%). Patients diagnosed in primary healthcare were more frequently asymptomatic than in hospital setting (36%; P<.001). The therapeutic strategy was based on the heart rate control in 4 out of 5 patients. Anticoagulation therapy was widely used (84%), more frequently in patients with permanent vs. non-permanent AF (91 vs. 60%, P<.001). Follow-up and monitoring was mainly performed in primary care (72%). The anticoagulation control was suboptimal, with a 66% of the international normalized ratio (INR) in therapeutic range, dropping to 33% when the last 3 available INR were included (P<.001).
CONCLUSIONS: A high rate of patients with anticoagulant therapy in primary healthcare has been found in this research. INR control, however, remains suboptimal. Heart rate control is the most commonly used strategy. The decision about the anticoagulation should be based on the thromboembolic risk rather than in the arrhytmia type.
Copyright © 2012 Elsevier España, S.L. All rights reserved.

Entities:  

Keywords:  Abordaje terapéutico; Anticoagulation therapy; Atención primaria; Atrial fibrillation; Clinical management; Fibrilación auricular; Primary healthcare; Tratamiento anticoagulante

Mesh:

Substances:

Year:  2013        PMID: 23683967     DOI: 10.1016/j.medcli.2012.12.023

Source DB:  PubMed          Journal:  Med Clin (Barc)        ISSN: 0025-7753            Impact factor:   1.725


  9 in total

1.  Improvement in the Management of Oral Anticoagulation in Patients with Atrial Fibrillation in Primary Health Care.

Authors:  África García-Roy; Ana Sarsa-Gómez; Fátima Méndez-López; Blanca Urdin-Muñoz; María Antonia Sánchez-Calavera
Journal:  Int J Environ Res Public Health       Date:  2022-05-31       Impact factor: 4.614

2.  [Prevalence of oral anticoagulation and quality of its management in primary healthcare: A study by the Health Sentinel Network of the Region of Valencia (Spain)].

Authors:  Ana Boned-Ombuena; Jordi Pérez-Panadés; Aurora López-Maside; Maite Miralles-Espí; Sandra Guardiola Vilarroig; Desamparados Adam Ruiz; Oscar Zurriaga
Journal:  Aten Primaria       Date:  2017-04-10       Impact factor: 1.137

3.  Efficacy of a joint didactic intervention using the Junta De Andalucía School for Patients method to control prothrombin time in patients taking anticoagulants: protocol for a randomized controlled trial.

Authors:  Leovigildo Ginel-Mendoza; Alfonso Hidalgo-Natera; Rocío Reina-Gonzalez; Rafael Poyato-Ramos; Juana Morales-Naranjo; Inmaculada Lupiañez-Pérez; Antonio Baca-Osorio; Miguel Gutiérrez-Jansen; María Paz Fernández-Lara; Diego Lozano-Noriega; Ulises Salgado-Carvallo; Cristina Bandera-García; Francisco Javier Navarro-Moya
Journal:  Trials       Date:  2021-01-11       Impact factor: 2.279

4.  Risk factors and therapeutic coverage at 6 years in patients with previous myocardial infarction: the CASTUO study.

Authors:  Francisco Javier Félix-Redondo; Luis Lozano Mera; Luciano Consuegra-Sánchez; Fernando Giménez Sáez; Francisco Javier Garcipérez de Vargas; José María Castellano Vázquez; Daniel Fernández-Bergés
Journal:  Open Heart       Date:  2016-02-26

5. 

Authors:  Carlos Brotons Cuixart; José Juan Alemán Sánchez; José Ramón Banegas Banegas; Carlos Fondón León; José María Lobos-Bejarano; Enrique Martín Rioboó; Jorge Navarro Pérez; Domingo Orozco-Beltrán; Fernando Villar Álvarez
Journal:  Aten Primaria       Date:  2018-05       Impact factor: 1.137

6.  [Fine-tuning of antithrombotic therapy in patients with non-valvular atrial fibrillation. The AFINVA register].

Authors:  Daniela Dubois Marques; Vicente Mora Llabata; Julián Pacheco Arroyo; Salvador Gasull Insertis; Manuela Vicente Cañizares; Ildefonso Roldán Torres
Journal:  Aten Primaria       Date:  2017-09-01       Impact factor: 1.137

7.  A new risk score to assess atrial fibrillation risk in hypertensive patients (ESCARVAL-RISK Project.

Authors:  Domingo Orozco-Beltran; Jose A Quesada; Vicente Bertomeu-Gonzalez; Jose M Lobos-Bejarano; Jorge Navarro-Perez; Vicente F Gil-Guillen; Luis Garcia Ortiz; Adriana Lopez-Pineda; Angel Castellanos-Rodriguez; Angela Lopez-Domenech; Antonio Francisco J Cardona-Llorens; Concepcion Carratala-Munuera
Journal:  Sci Rep       Date:  2020-03-16       Impact factor: 4.379

8.  [The family doctor and the barriers to prescribing the new oral anticoagulants: Heterogeneity, inequality and confusion. Statement of the Spanish Primary Care and Family Medicine Societies].

Authors:  José M Lobos Bejarano; José Polo García; Diego Vargas Ortega
Journal:  Aten Primaria       Date:  2013-11-21       Impact factor: 1.137

9.  Demographic, clinical, and functional determinants of antithrombotic treatment in patients with nonvalvular atrial fibrillation.

Authors:  Jose María Mostaza; Carmen Suarez; Jose María Cepeda; Luis Manzano; Demetrio Sánchez
Journal:  BMC Cardiovasc Disord       Date:  2021-08-09       Impact factor: 2.298

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.